This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== Typical views === Required projections can vary by country and hospital, although an erect posteroanterior (PA) projection is typically the first preference. If this is not possible, then an anteroposterior view will be taken. Further imaging depends on local protocols which is dependent on the hospital protocols, the availability of other imaging modalities and the preference of the image interpreter. In the UK, the standard chest radiography protocol is to take an erect posteroanterior view only and a lateral one only on request by a radiologist. In the US, chest radiography includes a PA and Lateral with the patient standing or sitting up. Special projections include an AP in cases where the image needs to be obtained stat (immediately) and with a portable device, particularly when a patient cannot be safely positioned upright. Lateral decubitus may be used for visualization of air-fluid levels if an upright image cannot be obtained. Anteroposterior (AP) Axial Lordotic projects the clavicles above the lung fields, allowing better visualization of the apices (which is extremely useful when looking for evidence of primary tuberculosis).
Domino's sponsored CART's Doug Shierson Racing, which was driven by Arie Luyendyk and won the 1990 Indianapolis 500. In 2003, Domino's teamed up with NASCAR for a multi-year partnership to become the "Official Pizza of NASCAR". Domino's also sponsored Michael Waltrip Racing and driver David Reutimann during the 2007 season in the NASCAR Sprint Cup Series. In June 2018, Domino's announced that it had started a project to pave over cracks and potholes on roads in the United States called "Paving for Pizza" to prevent their pizzas from being ruined, giving cities and towns grants for road repairs. The company had reached an agreement with four cities and towns, including Burbank, California; Bartonville, Texas; Athens, Georgia; and Milford, Delaware, to pave their roads. The paved sections feature the Domino's logo along with the slogan "OH YES, WE DID".
He was also listed in GQ India's "Best Dressed Men" rankings in 2010, 2012, 2015, and 2017. In 2023, he was placed 19th in 30 All Time Famous Bollywood Actors of All Time. Moreover, he was inducted into the Gladrags Hall of Fame.
Sources: en.wikipedia.org
Orlando Figes (born 1959) historian, author, known for works on Russian history; has also contributed on European history with his book The Europeans (2019); has served on editorial board of journal Russian History; writes for international press, broadcasts on television and radio, reviews for The New York Review of Books, and is fellow of Royal Society of Literature; was historical consultant on film Anna Karenina starring Keira Knightley and Jude Law with screenplay by Tom Stoppard; historical consultant on BBC War & Peace television series. Antonia Forest (26 May 1915 – 28 November 2003) was the pseudonym of Patricia Giulia Caulfield Kate Rubinstein, an English writer. She wrote 13 books for children, published between 1948 and 1982. Her 10 best-known works concern the doings of the fictional Marlow family. Forest also wrote two historical novels about the Marlows' Elizabethan ancestors. Dov Forman (b. 2003); author and social media creator; uses social media to educate people about the Holocaust and Judaism, and to advocate against antisemitism; co-authored Lily's Promise, a book documenting the Holocaust; received the 'Points of Light' award for services to Holocaust education; included in the inaugural TIME100 Creators list; was selected for the inaugural Masa Changemakers List, honouring 18 global leaders from Masa's 200,000+ alumni. Forman was a Masa participant during his time in Israel as a Nitzavim Fellow, studying at the Hebrew University of Jerusalem and a Talmudic college in Jerusalem.
Intermittent pain/discomfort or swelling above the anus or near the tailbone Opaque yellow (purulent) or bloody discharge from the tailbone area Unexpected moisture in the tailbone region Discomfort sitting on the tailbone, doing sit-ups, or riding a bicycle—any activities that roll over the tailbone area Some people with a pilonidal cyst will be asymptomatic.
== History == The concept of validation was first proposed by two Food and Drug Administration (FDA) officials, Ted Byers and Bud Loftus, in 1979 in USA, to improve the quality of pharmaceuticals. It was proposed in direct response to several problems in the sterility of large volume parenteral market. The first validation activities were focused on the processes involved in making these products, but quickly spread to associated processes including environmental control, media fill, equipment sanitization and purified water production. The concept of validation was first developed for equipment and processes and derived from the engineering practices used in delivery of large pieces of equipment that would be manufactured, tested, delivered and accepted according to a contract The use of validation spread to other areas of industry after several large-scale problems highlighted the potential risks in the design of products. The most notable is the Therac-25 incident. Here, the software for a large radiotherapy device was poorly designed and tested. In use, several interconnected problems led to several devices giving doses of radiation several thousands of times higher than intended, which resulted in the death of three patients and several more being permanently injured. In 2005 an individual wrote a standard by which the transportation process could be validated for cold chain products.
Sources: en.wikipedia.org
Neither the patient nor the healthcare provider knew which treatment was being given until after the trials. Treatment was given for 40 weeks. In the other three trials (NCT3987919, NCT03882970, and NCT03730662), participants were randomly assigned to receive either tirzepatide or another antidiabetic medication, and both the patient and the provider knew which medication was being given. Treatment was given for 40 weeks to 104 weeks. In each trial, HbA1c was measured from the start to the end of the trial and compared between the tirzepatide group and the other groups. Tirzepatide's efficacy for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight who had at least one weight-related condition. These studies measured weight reduction after 72 weeks in 2,519 participants who received either 5, 10, or 15 mg of tirzepatide once weekly and 958 participants who received weekly placebo injections. In both trials, after 72 weeks of treatment, participants who received tirzepatide at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of participants who received tirzepatide achieved at least 5% weight reduction compared to placebo.
=== Optical iridectomy === Optical iridectomy creates a clear entrance pupil, improving vision in patients with segmental corneal opacities. An area of clear peripheral cornea can produce retinal images compatible with good visual acuity.
Sexual dysfunction, including loss of libido, erectile dysfunction, lack of vaginal lubrication, and anorgasmia, are some of the most commonly encountered adverse effects of treatment with fluoxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%. In 2019, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that packaging leaflets of selected SSRIs and SNRIs should be amended to include information regarding a possible risk of persistent sexual dysfunction. Following on the European assessment, a safety review by Health Canada "could neither confirm nor rule out a causal link ... which was long lasting in rare cases", but recommended that "healthcare professionals inform patients about the potential risk of long-lasting sexual dysfunction despite discontinuation of treatment".
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.